In an experimental study, therapeutic blockade of interleukin 1 beta (IL-1β) and tumor necrosis alpha (TNF-a), which are major cytokines contributing to the endothelial damage post-CAR-T infusion and CRS/ICANS pathogenesis, have been found to protect against endothelial damage [31]. This evidence concerns the gene IL1B and congenital rubella syndrome.